Concord Biotech Limited — Q4 FY25 earnings call

Call held 30 May 2025

Management summary

Concord Biotech delivered a strong finish to FY25, characterized by significant revenue acceleration in Q4 and disciplined margin management. The company is successfully diversifying its portfolio away from heavy immunosuppressant reliance (now 74% of revenue) toward anti-infectives and high-potential injectables. Management is pivoting toward a CDMO model and targeting a long-term 25% CAGR, supported by newly commissioned capacities and a robust ANDA/DMF pipeline.

Highlights

  • Full year FY25 revenue reached ₹1,200 crores, representing 18% YoY growth.

  • Q4 FY25 revenue grew 35% YoY to ₹430 crores, driven by strong API and formulation performance.

  • Full year PAT stood at ₹372 crores, a 21% YoY increase with a 31% PAT margin.

  • EBITDA for FY25 grew 17% to ₹506 crores, with Q4 EBITDA margins at a robust 44.3%.

  • Commissioned a state-of-the-art injectable facility at Valthera with a potential turnover capacity of ₹600 crores.

  • API business grew 14% for the full year to ₹940 crores; Formulation business grew 38% to ₹260 crores.

  • Received US FDA approval for Teriflunomide tablets (ANDA) and filed 2 new DMFs for Nystatin and Voclosporin.

Key financials

  1. Revenue ₹1,200 Cr +18%YoY
  2. EBITDA ₹506 Cr +17%YoY
  3. EBITDA Margin 42.2%
  4. PAT ₹372 Cr +21%YoY
  5. PAT Margin 31%

What they filed

Q1 FY27: revenue up 27.9%, net profit up 41.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue310 244 430 204 247 −20%278 +14%326 −24%261 +28%
EBITDA137 98 190 61 91 −34%102 +4%122 −36%87 +43%
Net profit99 74 142 43 63 −36%68 −8%90 −37%61 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,200 Cr Total
  • API ₹940 Cr 78.3%
  • Formulation ₹260 Cr 21.7%

Guidance & targets

Revenue

  • Long-term CAGR Growth Revenue · Next 3-5 years · Medium confidence 25%

    Previously 18% → 25%

    So there is going to be a gradual progression towards going from 18% to 25%.

    — Ankur Vaid, MD and CEO

Capacity

  • Injectable Facility Turnover Potential Capacity · Full ramp-up · High confidence ₹600 crores
    I think during our calls also that it has the capability to give close to INR 600 crores of turnover.

    — Ankur Vaid, MD and CEO

Market Share

  • Teriflunomide US Market Share Market Share · Post-launch · Medium confidence 10-15%
    See, again, right now, we are not going with that; we would have a 10% or a 15% kind of a market share.

    — Ankur Vaid, MD and CEO

Capex

  • Maintenance Capex Capex · Annual · High confidence ₹20-30 crores
    we do not see any new capex happening over and above the maintenance capex of INR 20 crores, INR 30 crores that is there.

    — Ankur Vaid, MD and CEO

Market context

  • CDMO Revenue Contribution Revenue · Next 2-3 years · Medium confidence Double-digit

    From <1% today

    our intent or our efforts are to kind of get this CDMO business to a double-digit contributor to our sales numbers.

    — Ankur Vaid, MD and CEO

Risks & concerns

  • US FDA Regulatory Observations

    medium

    Dholka Unit 1 received 483 observations; management claims they are procedural and not related to data integrity.

    Management acknowledged

  • Gross Margin Volatility

    medium

    Sequential compression in gross margins due to product mix and internal transfer pricing dynamics.

    Analyst acknowledged

  • Lumpy Quarterly Performance

    low

    Management noted that procurement patterns can lead to uneven quarterly revenue, making full-year analysis more reliable.

    Management acknowledged

Areas of evasion (2)

  • Specific therapy-level revenue data beyond immunosuppressants.
  • Exact timeline for the CDMO business reaching double-digit contribution.

Q&A highlights

2 direct
Gross Margin Compression in Q4 Direct
This could be on account of change in the product mix... our API products, which are being transferred to formulation units happen at a market price and all the sales get booked in the formulation business.

Explains the 8% sequential dip in gross margins as a function of internal transfer pricing and product mix rather than fundamental pricing pressure.

Asked by Manoj Bahety, Carnelin Asset Management

CDMO Business Traction Partial
Currently, if you see, CDMO contributes less than 1% of business... our intent or our efforts are to kind of get this CDMO business to a double-digit contributor.

Highlights a major strategic shift toward high-margin CDMO work, though management is cautious about providing a specific timeline for the 'double-digit' target.

Asked by Vamsi Hota, Antique Stock Broking

Revenue Mix and 80-20 Ratio Sustainability Direct
The capacities have been designed such that the maximum output that you can get out of those capacities would end up having to be at the 80-20 split.

Confirms that despite faster growth in formulations, the physical infrastructure is capped to maintain the current API-heavy revenue mix.

Asked by Alok Dalal, Jefferies India

2 min read 5 chapters

Detailed narrative

Injectable Facility as the Next Growth Engine

Concord Biotech successfully commissioned its injectable facility at Valthera (Unit 4) in March 2025. Management highlighted that this state-of-the-art unit has the capacity to generate approximately ₹600 crores in annual turnover at full utilization. While revenue contribution will begin in FY26, a full ramp-up is expected over FY27 and FY28, providing a significant runway for the formulation segment which currently contributes only 22% of total revenue.

Strategic Pivot Toward CDMO and Diversification

The company is actively transitioning from a pure-play API manufacturer to an integrated CDMO partner. Although CDMO currently accounts for less than 1% of revenue, management has commercialized one project with an innovator and is in advanced discussions for 3-4 more. The goal is to move CDMO to a double-digit revenue contributor. Simultaneously, the share of immunosuppressants has dropped from 80% to 74% as anti-infectives gain traction.

Regulatory Compliance and Global Expansion

Regulatory milestones were a key theme, with the API facility at Dholka Unit 1 undergoing a US FDA inspection. While it resulted in 483 observations, management emphasized these were procedural and they expect an EIR shortly. Furthermore, the Valthera facility received an EU GMP certificate, and the company secured ANDA approval for Teriflunomide, targeting a 10-15% share of a $402 million US market.

Margin Dynamics and Operational Efficiency

Despite a sequential dip in gross margins in Q4, EBITDA margins remained strong at 44.3% for the quarter and 42.2% for the year. Management explained that internal transfers of API to the formulation unit at market prices can optically compress gross margins but are neutral at the EBITDA level. The company added 118 new customers in FY25, enhancing its operating leverage and reducing dependency on any single client.

Sustainability and ESG Integration

Concord made a strategic investment in Clean Max, a renewable energy company, to power its Dholka plant with wind and solar energy. This initiative is expected to significantly reduce the company's carbon footprint while providing long-term financial benefits through lower energy costs. This move aligns with their broader commitment to ESG principles as they scale global operations.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls